Post on 11-May-2015
description
NURSING IN-SERVICE: REMICADE®(INFLIXIMAB) IN GI PATIENTS
10A/B Surgery Ward, St. Paul’s Hospital
August 20 & 22, 2013
Joan Ng, B. Sc. Pharm, Pharmacy Resident
1
Outline 2
1. Introduction
2. Pharmacology
3. Indications
4. Side Effects
5. Contraindications
6. Drug Interactions
7. Practical Considerations
8. Question & Answer
What is Remicade®? 3
Generic drug name: Infliximab
Manufacturer: Janssen Inc.
Formulation: 100 mg/vial powder for solution (reconstituted by pharmacy), to be administered as an IV infusion
Drug Class: tumor necrosis factor alpha (TNF-α) inhibitor
Reference: 2
Pharmacology 4
TNF-α = pro-inflammatory cytokine
Infliximab = chimeric human-murine IgG MAb
Infliximab binds to TNF-α
Neutralizes TNF-α, blocks inflammation
Apoptosis of T-lymphocytes and monocytes
Down-regulation of other pro-inflammatory cytokines
Reference: 2-5
Indications (focus: GI) 5
Chronic inflammatory diseases
Crohn’s Disease (Moderate-Severe)
Ulcerative Colitis (Moderate-Severe)
For patients with inadequate response to conventional therapies
Induce and maintain remission
Maintain fistula closure (in fistulizing Crohn’s)
Induce and maintain mucosal healing (UC)
Reference: 2
Side Effects / Safety Concerns 6
Resp Upper respiratory tract infection (32%)
GI Nausea (21%)
Abdominal pain (12%; Crohn’s 26%)
Misc Antinuclear antibodies (~50%)
Infection (36%)
Infusion reactions (20%; severe <1%)
Malignancies (<5%)
Reference: 5-9
Contraindications 7
Hypersensitivity to infliximab, any component of the formulation
Doses >5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)
Severe infections
Sepsis, Abscesses
Tuberculosis
Opportunistic infections
Reference: 6
Drug Interactions 8
Other drugs that stimulate/suppress immune system
Vaccines
Inactivated
Live
Reference: 6
Practical: Screening/Preparation 9
TB Skin Test and follow-up CXR if (+)
Hepatitis B virus evaluation
Rule out infection/abscesses (C. diff, T, WBC)
Arrange for 1-to-1 nursing
Crohn's: Pharmacare Special Authority must be applied before start ($3000 per dose!)
Ulcerative Colitis: hospital provides first dose; if respond to first dose, then we submit to SA
Reference: 10
Practical: Drug Administration 10
I.V.: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
MD present for first 10 minutes of first dose
Follow Initial Infliximab Infusion Orders (PPO)
Infuse at 20 mL/hr x15mins, 80 mL/hr x15mins, 125 mL/hr until complete
Compatibility: Stable in NS; do not infuse with other agents
Reference: 6
Practical: Monitoring & SE Management 11
Vitals prior to start, q30 minutes during infusion, and at least 1 hour post-infusion
Monitor signs/symptoms of infusion reaction:
headache, flushing, pruritis, rash, hives, respiratory distress, swelling of lips or larynx, hypotension, abdominal pain, hypoxemia, flu-like symptoms
Follow PPO for management of acute reactions
Mild infusion reactions: monitor for min 6h
Anaphylactic reaction: monitor for min 24-48h
Questions? 12
References
1. Government of Canada HC. Drug Product Database Online Query [Internet]. 2012 [cited 2012 Sep 17]. Available from: http://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng
2. Infliximab: AHFS Drug Information [Internet]. [cited 2013 Aug 14]. Available from: http://www.medicinescomplete.com
3. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study. Gastroenterology. 2005 Jun;128(7):1805–11.
4. AccessMedicine | Tumor Necrosis Factor: The Other Primary Cytokine [Internet]. [cited 2013 Aug 14]. Available from: http://www.accessmedicine.com.ezproxy.library.ubc.ca
5. Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, et al. Infliximab in the treatment of Crohn’s disease. Ther Clin Risk Manag. 2007 Jun;3(2):301–8.
6. AccessMedicine | InFLIXimab [Internet]. [cited 2013 Aug 15]. Available from: http://www.accessmedicine.com.ezproxy.library.ubc.ca
7. Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006 Jul 26;8(4):R131.
8. Anker SD, Haehling S von. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004 Apr 1;90(4):464–70.
9. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation. 2003 Jul 1;107(25):3133–40.
10. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011 May 1;60(5):571–607.
13